Research pointers: Improvement in cholesterol emboli syndrome after iloprost therapy

BMJ. 2002 February 2; 324(7332): 268–269.

PMCID: PMC65057

Research pointers

Improvement in cholesterol emboli syndrome after iloprost therapy

Eran Elinav, resident,^a Tova Chajek-Shaul, professor of medicine,^a and Mirella Stern, senior physician^b

^aDepartment of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem 91240, Israel, ^bMedical Day Care Unit, Hadassah University Hospital, Ein Kerem, Jerusalem 91120, Israel

Contributed by

Contributors: All authors initiated the project and searched, extracted, analysed, and participated in discussing the results and writing the paper. TCS is the guarantor.

Correspondence to: T Chajek-Shaul chajek/at/hadassah.org.il

This article has been cited by other articles in PMC.

Iloprost therapy improved distal extremity lesions and renal function in patients with cholesterol emboli syndrome

Cholesterol emboli syndrome is a disorder in which multiple cholesterol crystals dislodge from atherosclerotic plaques, either spontaneously or after vascular interventions, treatment with anticoagulation, or thrombolytic treatment. The syndrome typically presents with painful ischaemic skin lesions, livedo reticularis, and acute renal failure. Treatments such as aspirin, statins, discontinuation of anticoagulation, and surgical correction of the embolic source are of limited efficacy.¹^,2 We report four cases of cholesterol emboli in which treatment with iloprost, a prostacyclin analogue,³ improved both ischaemia of the distal extremities and renal failure.

Patients and results

Four patients who had had a myocardial infarction and underwent procedures including coronary angiography, coronary bypass grafting surgery, and intra-aortic balloon pump implantation (table) presented within a month with cholesterol emboli syndrome. They had bilateral painful cyanotic ischaemic lesions of the toes with concomitant livedo reticularis in the presence of normal peripheral leg pulses. Skin biopsy from one of the ischaemic toe lesions showed cholesterol clefts. Despite treatment with aspirin, simvastatin, and dipyridamole and discontinuation of warfarin and heparin, pain intensity remained severe, new lesions appeared, and (in case 4) serum creatinine concentrations rose to 330 μmol/l.

Intravenous iloprost was administered continuously in gradually increasing doses up to 2 ng/kg/min for 10-14 days, followed by eight hour long infusions three times a week for an additional two to three weeks, and, thereafter, once a week. The rationale was to promote wound healing of the gangrenous lesions. At 30 days' follow up ischaemic lesions had entirely resolved and only those skin lesions featuring gangrenous changes at presentation did not improve. No new ischaemic lesions appeared in the toes. The pain in the extremities gradually resolved, as assessed by the need for narcotics and visual pain scale.

The fourth patient presented with cardiogenic shock, and an intra-aortic balloon pump was implanted. Serum creatinine concentrations rose from 105 μmol/l to 240 μmol/l during the first 10 days and then started to fall to 190 μmol/l on day 13. Then, in the absence of haemodynamic changes, it rose to 330 μmol/l on day 16, associated with ischaemic skin lesions and livido reticularis, cholesterol cleft on skin biopsy, eosinophilia, eosinophiluria, and hypocomplementaemia, all suggesting that the renal failure was related to cholesterol emboli. Iloprost therapy was started, and after 30 days of follow up the creatinine concentration was 240 μmol/l and remained so during long term follow up.

Side effects included transient drop in blood pressure in one patient, reversed by slowing of the infusion rate, and nausea, which necessitated discontinuation of iloprost therapy in two patients. After two days without iloprost the third patient developed new ischaemic lesions of the distal legs. Treatment was resumed at a slower rate and no new lesions were observed.

Comment

Patients suffering from cholesterol emboli syndrome, a progressive disease unresponsive to therapy, may benefit from iloprost. Administered to four patients suffering from multiple cholesterol emboli, iloprost caused the disappearance of most cyanotic lesions, with a dramatic relief of pain, and, in at least one patient, stabilised and subsequently improved renal function. These cases suggest that the drug should be initiated early to stabilise, and even reverse, the clinical syndrome, but only randomised controlled trials can provide firm evidence of a beneficial effect of iloprost in this syndrome.

In cholesterol emboli syndrome cholesterol crystals obstruct small arterioles, causing local ischaemia and end organ damage. Iloprost, a prostacyclin stable analogue used for treating critical leg ischaemia, Raynaud's syndrome, and pulmonary hypertension,³ is a potent vasodilator and antiplatelet aggregant, which stabilises endothelial integrity and has cytoprotective properties. This might explain our clinical observations in these four patients.

Table 1

Patients' characteristics, clinical presentation, treatments and response to iloprost

Footnotes

Funding: None.

Competing interest: None declared.

References

1. Kara HVK, Yunis JP, Mason RA, Giron F. After the blue toe: prognosis of noncardiac arterial embolization in the lower extremities. J Vasc Surg. 1993;17:328–335. [PubMed]

2. O'Keefe ST, Woods B, Breslin DJ, Tsapatsaris NP. Blue toe syndrome. Arch Intern Med. 1992;152:2197–2202. [PubMed]

3. Grant SM, Goa KL. Iloprost. Drugs. 1992;43:889–924. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of
BMJ Publishing Group